Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05988658 · ClinicalTrials.gov registry record
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
A clinical trial of Acute Kidney Injury and Biomarkers, sponsored by University of Chicago.
- Recruiting
- Registry status
- 800
- Enrollment target
- 2
- Study locations
NCT05988658: Recruiting study of Acute Kidney Injury and Biomarkers, sponsored by University of Chicago.
NCT05988658 is a study of Acute Kidney Injury and Biomarkers that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 800 participants, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05988658, a study of Acute Kidney Injury and Biomarkers, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk score will run in real time. The risk score will identify those patients with the highest risk for the future development of Stage 2 AKI and collect blood and urine for biomarker measurement over the subsequent 3 days.
Primary Outcome
Number of patients developing KDIGO Stage 2 AKI. KDIGO Stage 2 AKI defined as: A double of baseline serum creatinine from baseline OR 12 hours of urine output of less than 0.5ml/kg/hr in those with bladder catheters. If no catheter in place than urine output based AKI cannot be diagnosed
Conditions Studied
Interventions
- DEVICE ESTOP - AKI 2.0
Study Locations (2)
Illinois
- University of Chicago Medical Center - Chicago
Wisconsin
- University of Wisconsin Hospital - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2028-03-01 |
What NCT05988658 shows while recruiting
NCT05988658 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 2,320-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which ESTOP - AKI 2.0 is the first listed.
NCT05988658 reports a single indexed study location in Illinois, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05988658 about?
NCT05988658 is a clinical study titled "Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients". The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic...
What is the current status of trial NCT05988658?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2024-01-05. Estimated completion is 2028-03-01.
What conditions does trial NCT05988658 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Biomarkers.
What interventions are being tested in trial NCT05988658?
The interventions under investigation include: ESTOP - AKI 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05988658?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05988658 being conducted?
This trial has 2 study locations across Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05988658's enrollment target sits among peer trials
800 15th of 74 higher than 59 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI